Abstract
Recent studies have focused on decrease activity of paraoxonase (PON) in chronic kidney disease (CKD) patients. Paraoxonase (PON) enzyme is altered in many diseases and is related to lipid abnormalities and antioxidant activities. Patients with CKD often have lipid abnormalities. Lipid abnormalities in CKD patients increase the risk of cardiovascular diseases in CKD patients. In CKD patients, PON activity and its mechanism have developed a new idea for treatment options to reduce the risk of cardiovascular disease. This review article is focused on the role of PON in dyslipidemia in the CKD patients. © 2014 by Journal of Nephropathology (JNP).
Highlights
Implication for health policy/practice/research/medical education: Recent studies have focused on decrease activity of paraoxonase (PON) in chronic kidney disease (CKD) patients
In CKD patients, PON activity and its mechanism have developed a new idea for treatment options to reduce the risk of cardiovascular disease
PON activity decreases in patients with hyperthyroidism, hypothyroidism, and subclinical forms of thyroid diseases, and it is shown that the treatment of thyroid abnormalities can improve the enzyme activity in these patients [6,7,8,9]
Summary
Implication for health policy/practice/research/medical education: Recent studies have focused on decrease activity of paraoxonase (PON) in chronic kidney disease (CKD) patients. In CKD patients, PON activity and its mechanism have developed a new idea for treatment options to reduce the risk of cardiovascular disease. This review article is focused on the role of PON in dyslipidemia in the CKD patients. Paraoxonase enzyme activity and dyslipidemia in chronic kidney disease patients.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
